Qiaoyang Lu

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi

Amit Desai, Laura Kovanda, Donna Kowalski et al. · Antimicrobial Agents and Chemotherapy · 2016 · 140 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +15

Follow-up of patients with R/R <i>FLT3-</i>mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev et al. · Blood · 2022 · 137 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)

Laura Kovanda, Amit Desai, Qiaoyang Lu et al. · Antimicrobial Agents and Chemotherapy · 2016 · 71 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole

Laura Kovanda, Francisco M. Marty, Johan Maertens et al. · Antimicrobial Agents and Chemotherapy · 2017 · 68 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

Alexander E. Perl, Naoko Hosono, Pau Montesinos et al. · Blood Cancer Journal · 2022 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +16